BriaCell Therapeutics Corp. BCTX
BriaCell Therapeutics Corp. (Nasdaq: BCTX) is an oncology drug developer. Its lead program, Bria-IMT™ in combination with Retifanlimab®, is in Phase 3 for Metastatic breast cancer.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Bria-IMT™ + Retifanlimab® | Metastatic breast cancer | cell therapy | Phase 3 |
| Bria-OTS™ | Metastatic breast cancer | cell therapy | Phase 1 |
| Bria-BRES+™ | Breast cancer | cell therapy | Phase 1 |
| Bria-PROS+™ | Prostate cancer | cell therapy | Phase 1 |
| Bria-OVA+ | Ovarian cancer | cell therapy | Pre-clinical |
| Bria-MEL+ | Melanoma | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.